Live Breaking News & Updates on Its Selective Inhibitor Of Nuclear Export|Page 5

Stay updated with breaking news from Its selective inhibitor of nuclear export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $9.50

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have […] ....

Richarda Paulson , Michael Mason , Piper Sandler , Securities Exchange Commission , Prelude Capital Management , Karyopharm Therapeutics Inc , Its Selective Inhibitor Of Nuclear Export , Nisa Investment Advisors , Janney Montgomery Scott , Morgan Stanley , Life Insurance Co , Advisor Group Holdings Inc , Karyopharm Therapeutics , Get Rating , Exchange Commission , Investment Advisors , Group Holdings , Montgomery Scott , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti ,

Karyopharm Therapeutics (NASDAQ:KPTI) Trading 4.2% Higher

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) shares traded up 4.2% on Thursday . The stock traded as high as $7.74 and last traded at $7.66. 11,834 shares were traded during mid-day trading, a decline of 100% from the average session volume of 3,780,177 shares. The stock had previously closed at $7.35. Several research analysts […] ....

Nova Scotia , Sharon Shacham , Michael Mason , Frontier Capital Management Co , Karyopharm Therapeutics Inc , Morgan Stanley , Securities Exchange Commission , Blackrock Inc , Jpmorgan Chase Co , Its Selective Inhibitor Of Nuclear Export , Millennium Management , Royal Bank , Karyopharm Therapeutics , Get Rating , Exchange Commission , Capital Management , Odier Asset Management Switzerland , Selective Inhibitor , Nuclear Export , Nasdaq Kpti ,

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $11.83 Average Price Target from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) have been assigned a consensus recommendation of “Hold” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month target price […] ....

Hong Kong , Michael Kauffman , Sharon Shacham , Karyopharm Therapeutics Inc , Securities Exchange Commission , Commonwealth Equity Services , Karyopharm Therapeutics Company Profile Get Rating , Marshall Wace , Jpmorgan Chase Co , Its Selective Inhibitor Of Nuclear Export , Moors Cabot Inc , First Mercantile Trust Co , Royal Bank , Hong Kong Ltd , Karyopharm Therapeutics , Get Rating , Director Michael Kauffman , Exchange Commission , Kong Ltd , Equity Services , First Mercantile Trust , Mercantile Trust , Therapeutics Company Profile , Selective Inhibitor , Nuclear Export , Nasdaq Kpti ,

HC Wainwright Cuts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $22.00

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its price objective trimmed by HC Wainwright from $23.00 to $22.00 in a research report report published on Friday morning, MarketBeat reports. The firm currently has a buy rating on the stock. Several other equities analysts have also weighed in on the stock. SVB Leerink cut their price […] ....

Hong Kong , Thomson Reuter , Michael Kauffman , Sharon Shacham , Karyopharm Therapeutics Inc , Morgan Stanley , Commonwealth Equity Services , Marshall Wace , Jpmorgan Chase Co , Its Selective Inhibitor Of Nuclear Export , Moors Cabot Inc , First Mercantile Trust Co , Royal Bank , Hong Kong Ltd , Karyopharm Therapeutics , Get Rating , Director Michael Kauffman , Kong Ltd , Equity Services , First Mercantile Trust , Mercantile Trust , Selective Inhibitor , Nuclear Export , Nasdaq Kpti , Lower Price Target , Hc Wainwright ,